Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience
Clin. transl. oncol. (Print)
; 24(10): 20392043, octubre 2022. ilus, tab, graf
Article
in English
| IBECS
| ID: ibc-207959
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Purpose:
To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab.Methods/patientsPatients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if >5 Gy/fraction were delivered.ResultsAblative RT intent was the only independent predictor of both progression free and overall survival (HR 3.51, 95% CI 1.67.5, p = 0.0012 and HR 2.8, 95% CI 0.998.07, p = 0.05, respectively).ConclusionAblative RT may improve oncologic outcomes in selected patients with metastatic RCC treated with Nivolumab as compared to palliative RT. (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Carcinoma, Renal Cell
/
Nivolumab
/
Kidney Neoplasms
Limits:
Humans
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2022
Document type:
Article
Institution/Affiliation country:
Azienda Ospedaliera Universitaria Careggi/Italy
/
Careggi Hospital/Italy
/
IRCCS Sacro Cuore Don Calabria Hospital/Italy
/
Istituto Fiorentino di Cura e Assistenza/Italy
/
University and Spedali Civili Hospital/Italy